Methods Using a United Kingdom general population database, we conducted a cohort study of adult SLE patients, identified by Read codes. The exposures of interest were opioid prescriptions between January 1, 2007 and December 31, 2016. We classified opioids as weak, including tramadol and codeine, and strong, including hydrocodone, morphine, fentanyl, oxycodone, hydromorphone, and methadone. We examined the proportion of patients receiving prescriptions for weak and strong opioids and performed logistic regression to assess whether prescription use of these medications varied by age, sex, duration of SLE, other medication use for SLE, lifestyle exposures (alcohol and tobacco use), and socioeconomic status. We adjusted for age and sex.

Results Of 10,784 SLE patients, (86% female, mean age 51.2 years, 32%) were ever prescribed weak opioids (tramadol or codeine) and 10% were ever prescribed strong prescription opioids during the study period. 21% and 7% received multiple prescriptions for weak and strong opioids, respectively. Prescription opioid use was more common among older patients (adjusted OR 2.27 [95% CI: 1.91–2.70]) for weak opioid use and 2.94 [95% CI: 2.14–4.03] for strong opioid use among patients over age 50 compared with those under age 30. (Table 1). SLE patients who were also taking NSAIDs, DMARDs, or glucocorticoids each had an increased odds of receiving prescription opioids. Current smokers were also more likely to be prescribed prescription opioids. There was no significant association found between deprivation score, a measure of socioeconomic status, and opioid usage.

Conclusions In this general population-based cohort study, nearly one-third of SLE patients were ever prescribed weak opioids and 10% were ever prescribed stronger opioids. This rate of opioid prescription use is higher among patients who are also taking NSAIDs, glucocorticoids, and DMARDs. These findings indicate the use of these potentially dangerous medications among a substantial portion of SLE patients. Future studies should assess the impact of opioid usage on mortality and other important outcomes among patients with SLE.

Funding Source(s): NIH/NIAMS T32-AR-007258

158 CLINICAL AND SEROLOGICAL CORRELATIONS OF AUTOANTIBODIES DIRECTED AGAINST RNP-C IN SYSTEMIC LUPUS ERYTHEMATOSUS

May Choi1, Ann E Clarke2, Michelle Jung3, Claire Barber2, Yvan St Pierre2, Michael Muhler4, Marvin Fritzler5, Cumming School of Medicine, University of Calgary; 2Division of Rheumatology, Cumming School of Medicine, University of Calgary; 3University of Chicago; 4Department of Medicine, Division of Rheumatology, Faculty of Medicine, McGill University; 5Inova Diagnostics

Methods Using a United Kingdom general population database, we conducted a cohort study of adult SLE patients, identified by Read codes. The exposures of interest were opioid prescriptions between January 1, 2007 and December 31, 2016. We classified opioids as weak, including tramadol and codeine, and strong, including hydrocodone, morphine, fentanyl, oxycodone, hydromorphone, and methadone. We examined the proportion of patients receiving prescriptions for weak and strong opioids and performed logistic regression to assess whether prescription use of these medications varied by age, sex, duration of SLE, other medication use for SLE, lifestyle exposures (alcohol and tobacco use), and socioeconomic status. We adjusted for age and sex.

Results Of 10,784 SLE patients, (86% female, mean age 51.2 years, 32%) were ever prescribed weak opioids (tramadol or codeine) and 10% were ever prescribed strong prescription opioids during the study period. 21% and 7% received multiple prescriptions for weak and strong opioids, respectively. Prescription opioid use was more common among older patients (adjusted OR 2.27 [95% CI: 1.91–2.70]) for weak opioid use and 2.94 [95% CI: 2.14–4.03] for strong opioid use among patients over age 50 compared with those under age 30. (Table 1). SLE patients who were also taking NSAIDs, DMARDs, or glucocorticoids each had an increased odds of receiving prescription opioids. Current smokers were also more likely to be prescribed prescription opioids. There was no significant association found between deprivation score, a measure of socioeconomic status, and opioid usage.

Conclusions In this general population-based cohort study, nearly one-third of SLE patients were ever prescribed weak opioids and 10% were ever prescribed stronger opioids. This rate of opioid prescription use is higher among patients who are also taking NSAIDs, glucocorticoids, and DMARDs. These findings indicate the use of these potentially dangerous medications among a substantial portion of SLE patients. Future studies should assess the impact of opioid usage on mortality and other important outcomes among patients with SLE.

Funding Source(s): NIH/NIAMS T32-AR-007258

159 PEDIATRIC ONSET LUPUS WITH STEVENS JOHNSON SYNDROME/TOXIC EPIDERMAL NECROLYSIS: AN UNUSUAL ASSOCIATION

Himanshi Chaudhary1, Dhamnagat Bhattarai2, Pandarajyan Vignesh3, Amit Rawat1, Deepthi Suri, Sunil Dogra3, Surjit Singh1, Allergy Immunology Unit, Advanced Pediatrics Center, PGIMER Chandigarh; 2PGIMER, 3Dept. of Pediatrics, Allergy-Immunology Unit, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Methods We report an 11 year old girl who presented with an SJS/TEN rash and had other features consistent with SLE. Results An 11-year-old girl presented with history of alopecia, intermittent fever, a maculopapular rash progressing into patchy bullous and desquamating lesions, red scaly eyes and 2
episodes of generalized tonic clonic seizures. On examination, she had pallor, edema, oral ulcers and alopecia. She had distinct atypical targetoid lesions, diffuse erythematous rashes with denuded skin all over the face, trunk and extremities (involving >65% body surface area). There were bullae with positive Nikolsky sign. Deep tendon reflexes were brisk. Rest of the systemic examination was unremarkable.

Hemogram showed severe anemia, thrombocytopenia, lymphopenia and high erythrocyte sedimentation rate. Liver and kidney function tests were normal. Urinalysis showed subnephrotic range proteinuria. Antiphospholipid antibody workup (anti-cardiolipin IgG and IgM, 2 Glycoprotein I IgG and IgM, and lupus anticoagulant) was negative. Direct Coombs test was positive. Antinuclear antibody test by immunofluorescence was positive (4+ homogeneous with rim enhancement). Anti-DsDNA antibodies tested positive by both enzyme linked immunosorbent assay as well as by immunofluorescence.

Skin biopsy showed full thickness epidermal necrosis. Magnetic resonance imaging (MRI) brain revealed presence of cerebral atrophy with multiple small infarcts suggestive of vasculitic changes. On the basis of clinical and laboratory findings, a diagnosis of SJS/TEN in context of childhood onset lupus was proffered. She was treated with intravenous immunoglobulin, pulse methylprednisolone, antimicrobials and anti-convulsants along with supportive care. The child, however, succumbed to her illness.

Conclusions SJS/TEN may, at times, be the presenting feature of childhood lupus. The etiology of SJS/TEN in this patient is conjectural but is unlikely to be drug induced given the time course of events.

Funding Source(s): NIL.

FEELING THE BENEFIT: LUPUS AND THE WORLD OF WELFARE

1Sara Booth*, 2Elizabeth Price, 3Elizabeth Walker. 1University of Cambridge; 2Hull York Medical School; 3Faculty of Medical Sciences

10.1136/lupus-2019-lsm.160

Background This study explores peoples experiences of living and working with SLE whilst simultaneously navigating the contemporary UK welfare system. It is established that SLE is associated with high levels of workplace disability and early retirement from employment, requiring financial support. There is little literature about the experience of claiming benefits whilst living with a fluctuating, invisible medical condition, particularly in young people. Lupus is an exemplar of conditions which affect people in their most productive working years, treatable but not curable, which has profound effects on both educational and employment opportunities.

Methods A cross sectional online qualitative study was carried out of people aged 18 and over who were resident in the UK, with a self-reported diagnosis of lupus, through the LUPUS UK website. Participants responded to questions focusing on their experience of working and/or claiming benefits. Employment data is presented elsewhere. Participants were asked to to quantify (with numerical rating scales) (i) psychological distress associated with income loss resulting from lupus, (ii) the proportion of income lost (iii) any fear experienced of being unable to sustain future employment (iv) levels of anxiety generated by engaging with the benefits system. There was space to describe these experiences and for additional information of the participants choice.

Results A cross sectional online qualitative study was carried out of people aged 18 and over who were resident in the UK, with a self-reported diagnosis of lupus, through the LUPUS UK website. Participants responded to questions focusing on their experience of working and/or claiming benefits. Employment data is presented elsewhere. Participants were asked to to quantify (with numerical rating scales) (i) psychological distress associated with income loss resulting from lupus, (ii) the proportion of income lost (iii) any fear experienced of being unable to sustain future employment (iv) levels of anxiety generated by engaging with the benefits system. There was space to describe these experiences and for additional information of the participants choice.

Conclusions The experience of people with lupus claiming state support has been inadequately defined and explored so that it is variously, and inconsistently, understood, both by those requiring welfare and those administering it. We argue for a concerted focus on these issues in order to articulate more effectively this aspect of the experience of living with a chronic illness. The legislative and policy-driven processes, apparently designed to enable people with illness to live the most active working life possible, are not informed by scientific data, more is needed. The experiences of people with lupus are likely to be relevant to those with other similar illnesses where individuals may require long-term financial support with/out work.

Funding Source(s): No external funding required.

LOW HAPTOGLOBIN LEVEL IN LUPUS WITHOUT HEMOLYSIS

Homa Timlin, Johns Hopkins

10.1136/lupus-2019-lsm.161

Background Low haptoglobin indicates hemolysis in lupus patients. We present a lupus patient who was found to have low haptoglobin levels in the absence of other evidence of hemolysis.

Methods Chart review.

Results A 44-year-old Caucasian woman was diagnosed with lupus about 11 years ago, characterized by positive ANA, anti-DsDNA, antcardiolipin antibodies, anti-beta-2 glycoprotein, Direct Coombs, hypocomplementemia, alopecia, arthralgia, arthritis, photosensitive skin rash, serositis, mucosal ulcer, and livedo. She was treated with hydroxychloroquine, steroids, and Imuran. During her first visit in our center, she was found to have mild alopecia and subtype synovitis of 2 small joints. She was taking hydroxychloroquine 400 mg. The hematocrit was 34 (up from 30–31, 3 months prior to the visit and 3 months after the visit), haptoglobin 41 mg/dL (normal 43–34, platelet counts 2019; (Suppl 1):A1–A227